Galmed Pharma Shareholder Meeting Adjourned Due to Lack of Quorum
Ticker: GLMD · Form: 6-K · Filed: Oct 15, 2024 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, adjournment, quorum
TL;DR
Galmed Pharma's shareholder meeting postponed to Oct 21 due to no-shows, need quorum.
AI Summary
Galmed Pharmaceuticals Ltd. held a Special General Meeting of Shareholders on October 14, 2024, which was adjourned for one week due to a lack of quorum. The meeting will now reconvene on October 21, 2024, at 5:00 p.m. Israel time at the offices of Meitar Law Offices.
Why It Matters
The adjournment indicates potential shareholder disinterest or logistical issues, which could impact the company's ability to pass resolutions and move forward with corporate actions.
Risk Assessment
Risk Level: low — The adjournment is a procedural matter and does not inherently signal financial distress or operational failure.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Registrant
- October 14, 2024 (date) — Date of initial meeting
- October 21, 2024 (date) — Date of reconvened meeting
- Meitar Law Offices (company) — Legal counsel and meeting location
FAQ
Why was the Special General Meeting of Shareholders adjourned?
The meeting was adjourned due to a lack of quorum.
When will the Galmed Pharmaceuticals Ltd. meeting reconvene?
The meeting will reconvene on Monday, October 21, 2024.
What time is the reconvened meeting scheduled for?
The meeting is scheduled for 5:00 p.m. Israel time.
Where will the reconvened meeting take place?
The meeting will take place at the offices of Meitar | Law Offices.
What is the purpose of the Special General Meeting?
The filing does not specify the exact agenda items for the meeting, only that it is a Special General Meeting of Shareholders.
Filing Stats: 251 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-10-15 16:15:16
Filing Documents
- form6-k.htm (6-K) — 14KB
- 0001493152-24-041130.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: October 15, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer